NASDAQ · IBIO
Healthcare · Biotechnology
$1.45
Up+$0.00 (+0.00%)
Updated Aug 19, 2026, 10:37 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
IBIO closed at $1.45 after 21 trading sessions, up 2.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $1.45 | $1.47 | $1.40 | $1.45 | 2.79M |
| Aug 17, 2026 | $1.45 | $1.475 | $1.4226 | $1.45 | 589.28K |
| Aug 14, 2026 | $1.38 | $1.44 | $1.34 | $1.43 | 522.57K |
| Aug 13, 2026 | $1.48 | $1.48 | $1.38 | $1.40 | 507.81K |
| Aug 12, 2026 | $1.47 | $1.54 | $1.455 | $1.47 | 599.65K |
| Aug 11, 2026 | $1.41 | $1.505 | $1.37 | $1.47 | 375.07K |
| Aug 10, 2026 | $1.41 | $1.43 | $1.39 | $1.40 | 479.12K |
| Aug 7, 2026 | $1.40 | $1.425 | $1.375 | $1.41 | 436.39K |
| Aug 6, 2026 | $1.40 | $1.4119 | $1.36 | $1.39 | 424.31K |
| Aug 5, 2026 | $1.46 | $1.48 | $1.39 | $1.40 | 304.81K |
| Aug 4, 2026 | $1.46 | $1.49 | $1.44 | $1.46 | 486.24K |
| Aug 3, 2026 | $1.44 | $1.44 | $1.38 | $1.42 | 470.29K |
| Jul 31, 2026 | $1.41 | $1.47 | $1.34 | $1.40 | 728.59K |
| Jul 30, 2026 | $1.36 | $1.415 | $1.35 | $1.39 | 422.4K |
| Jul 29, 2026 | $1.39 | $1.41 | $1.29 | $1.36 | 802.9K |
| Jul 28, 2026 | $1.45 | $1.45 | $1.33 | $1.39 | 1.01M |
| Jul 27, 2026 | $1.44 | $1.47 | $1.35 | $1.45 | 1.05M |
| Jul 24, 2026 | $1.40 | $1.465 | $1.31 | $1.43 | 1.21M |
| Jul 23, 2026 | $1.35 | $1.41 | $1.33 | $1.40 | 464.67K |
| Jul 22, 2026 | $1.40 | $1.4073 | $1.35 | $1.38 | 370.36K |
| Jul 21, 2026 | $1.38 | $1.42 | $1.35 | $1.41 | 384.73K |
The latest Smart Investors Daily articles mentioning IBIO.
IBIO research
Company profile and research snapshot.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 2, 2026 | Chardan Capital | Buy | — |
| Jun 8, 2026 | Raymond James | Outperform | — |
| Apr 9, 2026 | Chardan Capital | Buy | — |
| Mar 18, 2026 | Chardan Capital | Buy | — |
| Mar 3, 2026 | Jones Trading | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 1, 2026
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approachWhen combined with semaglutide, IBIO-610 drove greater visceral and
Benzinga · Jun 8, 2026
Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $5.
Benzinga · Jun 2, 2026
iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first
Finnhub · May 12, 2026
iBio Inc: iBio reports Q3 fiscal year 2026 financial results and provides corporate update iBio Inc - reports no revenue for Q3 ended March 31, 2026 iBio Inc: Qtrly loss per share $-0.07...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBIO.
